These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 24479980)

  • 21. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
    Danese S; Panés J
    Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vedolizumab for the treatment of ulcerative colitis.
    Rietdijk ST; D'Haens GR
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):423-30. PubMed ID: 24802046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
    PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
    Saruta M; Papadakis KA
    Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    Panés J; Salas A
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects.
    Zundler S; Becker E; Weidinger C; Siegmund B
    Front Immunol; 2017; 8():891. PubMed ID: 28804488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of integrin antagonists in the treatment of inflammatory bowel disease.
    Beniwal-Patel P; Saha S
    Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-integrin therapy for inflammatory bowel disease.
    Park SC; Jeen YT
    World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
    Sands BE
    Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
    Dulai PS; Mosli M; Khanna R; Levesque BG; Sandborn WJ; Feagan BG
    Pharmacotherapy; 2015 Apr; 35(4):412-23. PubMed ID: 25884529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vedolizumab for the treatment of inflammatory bowel disease.
    Haddley K
    Drugs Today (Barc); 2014 Apr; 50(4):309-19. PubMed ID: 24918648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
    Schulze LL; Becker E; Dedden M; Liu LJ; van Passen C; Mohamed-Abdou M; Müller TM; Wiendl M; Ullrich KAM; Atreya I; Leppkes M; Ekici AB; Kirchner P; Stürzl M; Sexton D; Palliser D; Atreya R; Siegmund B; ; Neurath MF; Zundler S
    J Crohns Colitis; 2023 Nov; 17(11):1817-1832. PubMed ID: 37208197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?
    D'Amico F; Roda G; Peyrin-Biroulet L; Danese S
    Curr Pharm Des; 2019; 25(1):19-24. PubMed ID: 30848193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD.
    Duijvestein M; D'Haens GR
    Expert Opin Biol Ther; 2019 Apr; 19(4):361-366. PubMed ID: 30696342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
    Domènech E; Gisbert JP
    Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis.
    Besendorf L; Müller TM; Geppert CI; Schneider I; Mühl L; Atreya I; Vitali F; Atreya R; Neurath MF; Zundler S
    Therap Adv Gastroenterol; 2022; 15():17562848221098899. PubMed ID: 35784193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing.
    Sommer K; Heidbreder K; Kreiss L; Dedden M; Paap EM; Wiendl M; Becker E; Atreya R; Müller TM; Atreya I; Waldner M; Schürmann S; Friedrich O; Neurath MF; Zundler S
    Clin Transl Med; 2023 Apr; 13(4):e1233. PubMed ID: 37029786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.
    Allocca M; Gilardi D; Fiorino G; Furfaro F; Argollo M; Peyrin-Biroulet L; Danese S
    Expert Opin Investig Drugs; 2018 Jul; 27(7):623-629. PubMed ID: 29985060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
    Wyant T; Fedyk E; Abhyankar B
    J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-adhesion molecules: is gut specificity the key for a good safety profile?
    Allen PB
    Curr Drug Deliv; 2012 Jul; 9(4):333-7. PubMed ID: 22762276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.